Cardiology (HF)

In patients diagnosed with HF, prognostic information on future risk for hospital readmission and/or death is useful for both caregivers and patients. Prognostic information may assist clinicians in planning discharge decisions and the intensity of follow-up visits. It may also guide physicians in patient management decisions concerning further medical or surgical intervention. Biomarkers such as NT-proBNP and galectin-3 have been shown to provide incremental independent prognostic information. 

VIDAS® Galectin-3

 VIDAS<sup>®</sup> Galectin-3

Aid in risk stratification of Heart Failure patients

VIDAS® NT-proBNP2

 VIDAS<sup>®</sup> NT-proBNP2

Exclusion or confirmation of acute Heart Failure

VIDAS® Digoxin

 VIDAS<sup>®</sup> Digoxin

Monitor treatment to ensure appropriate therapy

Pioneering Diagnostics